South Boston, VA, United States of America

Stephen A Wring

This inventor holds 1 USPTO granted patent and 6 published patent applications. Top assignee: Altavant Sciences Gmbh. Active years: 2023.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2023

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Stephen A. Wring

Introduction

Stephen A. Wring is an accomplished inventor based in South Boston, Virginia. He has made significant contributions to the field of medicine, particularly in the treatment of pulmonary arterial hypertension. His innovative approach has led to the development of a unique dosage regimen that aims to improve patient outcomes.

Latest Patents

Stephen A. Wring holds a patent for a dosage regime and method for treating pulmonary arterial hypertension. This patent outlines a daily dosage regimen that consists of two discrete dosage forms. Each dosage form contains an amount ranging from about 600 mg to about 800 mg of (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1'-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate. Additionally, the patent provides methods for reducing serotonin biosynthesis by at least 50% and achieving specific pharmacokinetic parameters.

Career Highlights

Stephen A. Wring is currently associated with Altavant Sciences GmbH, where he continues to work on innovative solutions for pulmonary arterial hypertension. His expertise and dedication to research have positioned him as a key figure in the development of new therapeutic strategies.

Collaborations

Stephen collaborates with talented professionals in his field, including Michelle Palacios and Eric J. Gaukel. Their combined efforts contribute to advancing research and innovation in pulmonary health.

Conclusion

Stephen A. Wring's contributions to the field of medicine through his patent and work at Altavant Sciences GmbH highlight his commitment to improving treatment options for patients with pulmonary arterial hypertension. His innovative spirit and collaborative approach continue to drive advancements in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…